Literature DB >> 9049593

Effects of Boswellia serrata gum resin in patients with ulcerative colitis.

I Gupta1, A Parihar, P Malhotra, G B Singh, R Lüdtke, H Safayhi, H P Ammon.   

Abstract

Ulcerative colitis is a chronic inflammatory disease of the colon where leukotrienes are suggested to play an important role for keeping inflammation active. Boswellic acids, the biologically active ingredients of the gum resin of Boswellia serrata (Sallai guggal), have been shown to be specific, nonredox and noncompetitive inhibitors of 5-lipoxygenase, the key enzyme of leukotriene biosynthesis. In patients suffering from ulcerative colitis grade II and III the effect of Boswellia serrata gum resin preparation (350 mg thrice daily for 6 weeks) on stool properties, histolopathology and scan microscopy of rectal biopsies, blood parameters including Hb, serum iron, calcium, phosphorus, proteins, total leukocytes and eosinophils was studied. Patients receiving sulfasalazine (1 g thrice daily) served as controls. All parameters tested improved after treatment with Boswellia serrata gum resin, the results being similar compared to controls: 82% out of treated patients went into remission; in case of sulfasalazine remission rate was 75%.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9049593

Source DB:  PubMed          Journal:  Eur J Med Res        ISSN: 0949-2321            Impact factor:   2.175


  46 in total

1.  Effect of Boswellia serrata on intestinal motility in rodents: inhibition of diarrhoea without constipation.

Authors:  Francesca Borrelli; Francesco Capasso; Raffaele Capasso; Valeria Ascione; Gabriella Aviello; Rocco Longo; Angelo A Izzo
Journal:  Br J Pharmacol       Date:  2006-04-24       Impact factor: 8.739

Review 2.  A review of the efficacy of traditional Iranian medicine for inflammatory bowel disease.

Authors:  Roja Rahimi; Mohammad Reza Shams-Ardekani; Mohammad Abdollahi
Journal:  World J Gastroenterol       Date:  2010-09-28       Impact factor: 5.742

3.  European evidence based consensus on the diagnosis and management of Crohn's disease: special situations.

Authors:  R Caprilli; M A Gassull; J C Escher; G Moser; P Munkholm; A Forbes; D W Hommes; H Lochs; E Angelucci; A Cocco; B Vucelic; H Hildebrand; S Kolacek; L Riis; M Lukas; R de Franchis; M Hamilton; G Jantschek; P Michetti; C O'Morain; M M Anwar; J L Freitas; I A Mouzas; F Baert; R Mitchell; C J Hawkey
Journal:  Gut       Date:  2006-03       Impact factor: 23.059

Review 4.  Review on efficacy and health services research studies of complementary and alternative medicine in inflammatory bowel disease.

Authors:  Stefanie Joos
Journal:  Chin J Integr Med       Date:  2011-06-10       Impact factor: 1.978

5.  Identification of novel anti-inflammatory agents from Ayurvedic medicine for prevention of chronic diseases: "reverse pharmacology" and "bedside to bench" approach.

Authors:  Bharat B Aggarwal; Sahdeo Prasad; Simone Reuter; Ramaswamy Kannappan; Vivek R Yadev; Byoungduck Park; Ji Hye Kim; Subash C Gupta; Kanokkarn Phromnoi; Chitra Sundaram; Seema Prasad; Madan M Chaturvedi; Bokyung Sung
Journal:  Curr Drug Targets       Date:  2011-10       Impact factor: 3.465

Review 6.  Drug-Herb Interactions in the Elderly Patient with IBD: a Growing Concern.

Authors:  Haider Rahman; Marina Kim; Galen Leung; Jesse A Green; Seymour Katz
Journal:  Curr Treat Options Gastroenterol       Date:  2017-12

7.  Metabolic Profile of 3-Acetyl-11-Keto-β-Boswellic Acid and 11-Keto-β-Boswellic Acid in Human Preparations In Vitro, Species Differences, and Bioactivity Variation.

Authors:  Yonglei Cui; Xiangge Tian; Jing Ning; Chao Wang; Zhenlong Yu; Yan Wang; Xiaokui Huo; Lingling Jin; Sa Deng; Baojing Zhang; Xiaochi Ma
Journal:  AAPS J       Date:  2016-06-21       Impact factor: 4.009

8.  Boswellic acid inhibits growth and metastasis of human colorectal cancer in orthotopic mouse model by downregulating inflammatory, proliferative, invasive and angiogenic biomarkers.

Authors:  Vivek R Yadav; Sahdeo Prasad; Bokyung Sung; Juri G Gelovani; Sushovan Guha; Sunil Krishnan; Bharat B Aggarwal
Journal:  Int J Cancer       Date:  2011-09-12       Impact factor: 7.396

9.  Boswellia serrata extract for the treatment of collagenous colitis. A double-blind, randomized, placebo-controlled, multicenter trial.

Authors:  Ahmed Madisch; Stephan Miehlke; Otto Eichele; Jenny Mrwa; Birgit Bethke; Eberhard Kuhlisch; Elke Bästlein; Georg Wilhelms; Andrea Morgner; Bernd Wigginghaus; Manfred Stolte
Journal:  Int J Colorectal Dis       Date:  2007-09-02       Impact factor: 2.571

10.  The selective 5-LOX inhibitor 11-keto-β-boswellic acid protects against myocardial ischemia reperfusion injury in rats: involvement of redox and inflammatory cascades.

Authors:  Shimaa M Elshazly; Dalia M Abd El Motteleb; Noha N Nassar
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-06-15       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.